almorexant and Hypertension

almorexant has been researched along with Hypertension* in 3 studies

Other Studies

3 other study(ies) available for almorexant and Hypertension

ArticleYear
Contribution of Orexin to the Neurogenic Hypertension in BPH/2J Mice.
    Hypertension (Dallas, Tex. : 1979), 2016, Volume: 67, Issue:5

    BPH/2J mice are a genetic model of hypertension associated with an overactive sympathetic nervous system. Orexin is a neuropeptide which influences sympathetic activity and blood pressure. Orexin precursor mRNA expression is greater in hypothalamic tissue of BPH/2J compared with normotensive BPN/3J mice. To determine whether enhanced orexinergic signaling contributes to the hypertension, BPH/2J and BPN/3J mice were preimplanted with radiotelemetry probes to compare blood pressure 1 hour before and 5 hours after administration of almorexant, an orexin receptor antagonist. Mid frequency mean arterial pressure power and the depressor response to ganglion blockade were also used as indicators of sympathetic nervous system activity. Administration of almorexant at 100 (IP) and 300 mg/kg (oral) in BPH/2J mice during the dark-active period (2 hours after lights off) markedly reduced blood pressure (-16.1 ± 1.6 and -11.0 ± 1.1 mm Hg, respectively;P<0.001 compared with vehicle). However, when almorexant (100 mg/kg, IP) was administered during the light-inactive period (5 hours before lights off) no reduction from baseline was observed (P=0.64). The same dose of almorexant in BPN/3J mice had no effect on blood pressure during the dark (P=0.79) or light periods (P=0.24). Almorexant attenuated the depressor response to ganglion blockade (P=0.018) and reduced the mid frequency mean arterial pressure power in BPH/2J mice (P<0.001), but not BPN/3J mice (P=0.70). Immunohistochemical labeling revealed that BPH/2J mice have 29% more orexin neurons than BPN/3J mice which are preferentially located in the lateral hypothalamus. The results suggest that enhanced orexinergic signaling contributes to sympathetic overactivity and hypertension during the dark period in BPH/2J mice.

    Topics: Acetamides; Administration, Oral; Animals; Biomarkers; Blood Pressure Determination; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension; Injections, Intraperitoneal; Isoquinolines; Male; Mice; Mice, Transgenic; Motor Activity; Orexins; Pressoreceptors; Random Allocation; Reference Values; Renin-Angiotensin System; Sympathetic Nervous System; Treatment Outcome

2016
Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats.
    The Journal of physiology, 2013, Sep-01, Volume: 591, Issue:17

    In normal rats, central administration of orexin or exposure to certain forms of stress can induce significant increases in blood pressure and sympathetic nerve activity, which can be blocked by orexin receptor antagonists. The resting blood pressure is, however, unaffected by such antagonists, but is significantly lower in rodents with total loss of orexin, such as prepro-orexin knockout mice and orexin neuron-ablated orexin/ataxin-3 transgenic rats. We hypothesize that orexin is involved in the pathophysiology and maintenance of high blood pressure in the spontaneously hypertensive rat (SHR), a model of primary hypertension. To test this hypothesis, we measured orexin-A mRNA expression in the rostral ventrolateral medulla and antagonized both orexin receptors using an orally administered potent dual orexin receptor antagonist, almorexant, in SHRs and normotensive Wistar-Kyoto rats. In SHRs, there was a strong trend towards an increased orexin-A mRNA expression in the rostral ventrolateral medulla, and blocking orexin receptors markedly lowered blood pressure (from 182/152 ± 5/6 to 149/119 ± 9/8 mmHg; P < 0.001), heart rate (P < 0.001), sympathetic vasomotor tone (P < 0.001) and the noradrenaline levels in cerebrospinal fluid and plasma (P < 0.002). The significant antihypertensive effects of almorexant were observed in wakefulness and non-rapid eye movement sleep during both dark and light phases of the diurnal cycle only in SHRs. Blocking orexin receptors had no effect on blood pressure and sympathetic tone in normotensive Wistar-Kyoto rats. Our study links the orexin system to the pathogenesis of high blood pressure in SHRs and suggests that modulation of the orexin system could be a potential target in treating some forms of hypertension.

    Topics: Acetamides; Animals; Blood Pressure; Hypertension; Isoquinolines; Medulla Oblongata; Norepinephrine; Orexin Receptor Antagonists; Orexin Receptors; Rats; Rats, Inbred SHR; Rats, Inbred WKY; RNA, Messenger

2013
Treating hypertension by targeting orexin receptors: potential effects on the sleep-related blood pressure dipping profile.
    The Journal of physiology, 2013, Dec-01, Volume: 591, Issue:23

    Topics: Acetamides; Animals; Antihypertensive Agents; Blood Pressure; Hypertension; Isoquinolines; Orexin Receptor Antagonists; Rats; Sleep

2013